• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经 CCR5Δ32/Δ32 干细胞移植实现 HIV 感染治愈的证据。

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.

机构信息

Department of Gastroenterology, Infectious Diseases, and Rheumatology, Medical Clinic I, Campus Benjamin Franklin, Charité-University Medicine Berlin, Berlin, Germany.

出版信息

Blood. 2011 Mar 10;117(10):2791-9. doi: 10.1182/blood-2010-09-309591. Epub 2010 Dec 8.

DOI:10.1182/blood-2010-09-309591
PMID:21148083
Abstract

HIV entry into CD4(+) cells requires interaction with a cellular receptor, generally either CCR5 or CXCR4. We have previously reported the case of an HIV-infected patient in whom viral replication remained absent despite discontinuation of antiretroviral therapy after transplantation with CCR5Δ32/Δ32 stem cells. However, it was expected that the long-lived viral reservoir would lead to HIV rebound and disease progression during the process of immune reconstitution. In the present study, we demonstrate successful reconstitution of CD4(+) T cells at the systemic level as well as in the gut mucosal immune system after CCR5Δ32/Δ32 stem cell transplantation, while the patient remains without any sign of HIV infection. This was observed although recovered CD4(+) T cells contain a high proportion of activated memory CD4(+) T cells, ie, the preferential targets of HIV, and are susceptible to productive infection with CXCR4-tropic HIV. Furthermore, during the process of immune reconstitution, we found evidence for the replacement of long-lived host tissue cells with donor-derived cells, indicating that the size of the viral reservoir has been reduced over time. In conclusion, our results strongly suggest that cure of HIV has been achieved in this patient.

摘要

HIV 进入 CD4(+) 细胞需要与细胞受体相互作用,通常是 CCR5 或 CXCR4。我们之前曾报道过一例 HIV 感染患者,在接受 CCR5Δ32/Δ32 干细胞移植后停止抗逆转录病毒治疗,但病毒复制仍然不存在。然而,人们预计长期存在的病毒库会在免疫重建过程中导致 HIV 反弹和疾病进展。在本研究中,我们证明了在 CCR5Δ32/Δ32 干细胞移植后,系统性和肠道黏膜免疫系统中的 CD4(+) T 细胞成功重建,而患者仍然没有任何 HIV 感染的迹象。尽管恢复的 CD4(+) T 细胞含有大量活化的记忆 CD4(+) T 细胞,即 HIV 的优先靶标,并且容易被 CXCR4 嗜性 HIV 进行有效感染,但仍观察到这种情况。此外,在免疫重建过程中,我们发现了宿主组织细胞被供体衍生细胞替代的证据,表明病毒库的大小随着时间的推移而减少。总之,我们的结果强烈表明,该患者已实现 HIV 的治愈。

相似文献

1
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.经 CCR5Δ32/Δ32 干细胞移植实现 HIV 感染治愈的证据。
Blood. 2011 Mar 10;117(10):2791-9. doi: 10.1182/blood-2010-09-309591. Epub 2010 Dec 8.
2
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.HIV-1 缓解后 CCR5Δ32/Δ32 造血干细胞移植。
Nature. 2019 Apr;568(7751):244-248. doi: 10.1038/s41586-019-1027-4. Epub 2019 Mar 5.
3
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.通过CCR5 Δ32/Δ32干细胞移植实现对HIV的长期控制。
N Engl J Med. 2009 Feb 12;360(7):692-8. doi: 10.1056/NEJMoa0802905.
4
Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.糖基磷脂酰肌醇锚定的抗HIV单链抗体片段可有效保护人外周血淋巴细胞小鼠中的CD4 T细胞免受HIV-1感染和缺失。
J Virol. 2017 Jan 18;91(3). doi: 10.1128/JVI.01389-16. Print 2017 Feb 1.
5
CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.HIV 感染者接受 CCR5Δ32 纯合子脐带血异基因移植:病例报告。
Lancet HIV. 2015 Jun;2(6):e236-42. doi: 10.1016/S2352-3018(15)00083-1. Epub 2015 May 19.
6
CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy.CCR5Δ32突变与HIV感染:治愈性HIV治疗的基础
Curr Opin Virol. 2015 Oct;14:24-9. doi: 10.1016/j.coviro.2015.06.007. Epub 2015 Jul 1.
7
TALENs-mediated homozygous CCR5Δ32 mutations endow CD4+ U87 cells with resistance against HIV‑1 infection.TALENs 介导的 CCR5Δ32 基因突变使 CD4+ U87 细胞对 HIV-1 感染具有抗性。
Mol Med Rep. 2018 Jan;17(1):243-249. doi: 10.3892/mmr.2017.7889. Epub 2017 Oct 26.
8
Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report.抗逆转录病毒治疗中断 30 个月后 CCR5Δ32/Δ32 异基因造血干细胞移植治疗 HIV-1 治愈的证据:一例报告。
Lancet HIV. 2020 May;7(5):e340-e347. doi: 10.1016/S2352-3018(20)30069-2. Epub 2020 Mar 10.
9
Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1.HIV-1 感染治疗研究的新进展:针对 HIV-1 潜伏库。
J Allergy Clin Immunol. 2014 Jul;134(1):12-9. doi: 10.1016/j.jaci.2014.05.026. Epub 2014 Jun 26.
10
Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice.在人源化 BLT 小鼠的造血干/祖细胞中,通过短发夹 RNA 表达工程产生抗 HIV-1 的 T 细胞。
PLoS One. 2012;7(12):e53492. doi: 10.1371/journal.pone.0053492. Epub 2012 Dec 31.

引用本文的文献

1
Design and characterization of HIV-1 vaccine candidates to elicit antibodies targeting multiple epitopes.用于引发靶向多个表位的抗体的HIV-1候选疫苗的设计与特性分析
J Exp Med. 2025 Oct 6;222(10). doi: 10.1084/jem.20250693. Epub 2025 Aug 12.
2
Lymphoproliferations in People Living with HIV: Oncogenic Pathways, Diagnostic Challenges, and New Therapeutic Opportunities.HIV感染者的淋巴细胞增殖:致癌途径、诊断挑战及新的治疗机遇
Cancers (Basel). 2025 Jun 22;17(13):2088. doi: 10.3390/cancers17132088.
3
The power of ten in HIV remission: insights from hematopoietic stem cell transplantation.
HIV缓解中的十的力量:造血干细胞移植的见解
Curr Opin HIV AIDS. 2025 Sep 1;20(5):456-462. doi: 10.1097/COH.0000000000000954. Epub 2025 Jul 9.
4
Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection.基于造血干细胞的抗HIV-1基因疗法,带有安全杀灭开关以抵御和对抗HIV-1感染。
Mol Ther Methods Clin Dev. 2025 May 15;33(2):101486. doi: 10.1016/j.omtm.2025.101486. eCollection 2025 Jun 12.
5
Fast pH-Driven Solubilization Method of Realgar (AsS) to Reduce the Toxicity of Arsenic [As(III)] for Medicinal Purposes.用于药用目的的雄黄(AsS)快速pH驱动增溶方法以降低砷[As(III)]的毒性
Adv Sci (Weinh). 2025 Aug;12(29):e2502740. doi: 10.1002/advs.202502740. Epub 2025 Apr 24.
6
Matters Arising: on the willingness to trade-off years of life for an HIV cure.相关问题:关于用多年生命换取治愈艾滋病的意愿。
AIDS Res Ther. 2025 Feb 27;22(1):25. doi: 10.1186/s12981-025-00723-x.
7
Persistent elite controllers as the key model to identify permanent HIV remission.持续精英控制者作为识别HIV永久缓解的关键模型。
Curr Opin HIV AIDS. 2025 Mar 1;20(2):165-171. doi: 10.1097/COH.0000000000000907. Epub 2025 Jan 17.
8
Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection.基于造血干细胞的抗HIV-1基因疗法,带有安全杀伤开关以抵御和对抗HIV-1感染。
bioRxiv. 2024 Nov 13:2024.11.13.623476. doi: 10.1101/2024.11.13.623476.
9
Interventions during Early Infection: Opening a Window for an HIV Cure?早期感染期的干预措施:为 HIV 治愈打开一扇窗?
Viruses. 2024 Oct 9;16(10):1588. doi: 10.3390/v16101588.
10
Advancing towards HIV-1 remission: Insights and innovations in stem cell therapies.迈向HIV-1缓解:干细胞疗法的见解与创新
Arch Stem Cell Ther. 2024;5(1):5-13. doi: 10.46439/stemcell.5.020.